Denali Therapeutics Inc.
DNLI· Nasdaq
Released Nov 6, 2025, after the close
10-Q filed Nov 6, 2025, 37 days after period end · 0001714899-25-000193
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.27M | $184.00K |
| Net Income | -$126.90M | -$107.19M | -$99.35M | -$103.30M |
| EPS Diluted |
Denali Therapeutics Inc. · CIK 1714899 · Engraved from SEC EDGAR
| -$0.74 |
| -$0.63 |
| -$0.72 |
| -$0.84 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.